RE: SourceBio International - hidden gem13 Nov 2020 01:13
GW, caught some of the presentation whilst working, but need to listen through the recording again.
As you say, revenue looks healthy and good margins across the business (diagnostics 40%, stability storage 80%, testing 40%, not sure about Genomics). Didn't pick up any mention of expanding testing capacity further(?) beyond what they are able to do on the 2nd floor of the lab, but that's not the plan medium to long term. Personally quite liked the approach - no R&D, no patents, just good at what we do - which differs to some other shares I'm in. Like the plan to use the testing warchest for careful acquisitions.
They're the experts of course, but I think their forecast that testing will peak in mid-21 before a slow decline is cautious. You've probably seen the figures posted on other BBs this evening - fear of side effects will limit vaccines uptake unfortunately, immunity may not last, regular testing of front-line medical staff estimated at 60 million globally by WHO, ongoing testing for a fraction of the 4.1 billion air passengers each year etc.